VanEck Biotech ETF
Price through Oct 6, 2026 · Flows through Oct 5, 2026. Figures use the latest available records, not a live quote. Fund details retrieved Oct 6, 2026. Holdings snapshot retrieved Oct 6, 2026.
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
SOURCE: MARKET TAPE & DAILY CREATION/REDEMPTION RECORDS · 6M SHOWN · NET +$9M OVER THIS RANGE
Money is leaving — −$5M in net outflows over the past month, about 1.0% of the fund's asset base, while the price has returned +24.9% so far this year. At 0.35% a year it is not the cheapest way in — IWM has a reported fee of 0.19%.
COMPOSED FROM THE FUND’S OWN DAILY RECORDS · UPDATED WITH EACH REFRESH
CELL SIZE IS PORTFOLIO WEIGHT · COLOR IS THE CHANGE IN THE LATEST AVAILABLE SNAPSHOT · TOP 40 POSITIONS
| # | Holding | Weight | Price | Day | 52-wk | |
|---|---|---|---|---|---|---|
| 1 | AMGNAMGEN | 15.53% | $402.60 | -0.1% | ||
| 2 | GILDGILEAD SCIENCES | 13.18% | $144.23 | -0.3% | ||
| 3 | VRTXVERTEX PHARMACEUTICALS | 8.17% | $502.31 | -0.2% | ||
| 4 | REGNREGENERON PHARMACEUTICALS | 6.49% | $738.72 | +1.7% | ||
| 5 | MRNAMODERNA | 6.16% | $187.46 | -7.8% | ||
| 6 | NTRANATERA | 5.46% | $400.65 | -5.9% | ||
| 7 | ARGXARGENX SE | 4.53% | $930.52 | +1.9% | ||
| 8 | IQVIQVIA HOLDINGS | 4.42% | $259.98 | -2.3% | ||
| 9 | RVMDREVOLUTION MEDICINES | 4.37% | $199.87 | -3.8% | ||
| 10 | ILMNILLUMINA | 4.15% | $273.54 | -6.9% | ||
| 11 | GHGUARDANT HEALTH | 3.09% | $170.69 | -8.8% | ||
| 12 | ONCBeiGene | 2.78% | $362.78 | +0.3% | ||
| 13 | BIIBBIOGEN | 2.74% | $222.89 | -0.3% | ||
| 14 | ALNYALNYLAM PHARMACEUTICALS | 2.48% | $223.94 | +1.8% | ||
| 15 | UTHRUNITED THERAPEUTICS | 2.31% | $541.62 | +1.0% |
The full book, free with one sign-in.
Top 15 positions are open to everyone. Sign in once and every fund’s complete holdings — plus CSV export, watchlists, and flow alerts — unlock across the network.
Sign in to see all 26| 1 week | -3.4% |
| 1 month | -2.0% |
| 3 months | +12.3% |
| 6 months | +25.8% |
| YTD | +24.9% |
| 1 year | +35.7% |
| 3 years | — |
PRICE RETURN, DISTRIBUTIONS NOT REINVESTED
| 1 week | +$2M |
| 1 month | −$5M |
| 3 months | +$15M |
| YTD | +$7M |
| 1 year | −$21M |
CREATION/REDEMPTION DOLLARS, DAILY RECORDS
The top holding is 15.5% of the book; the top ten carry 72%. Spread across 25+ names, it behaves like roughly 14 equally-weighted positions.
VOLATILITY & DRAWDOWN FROM THE DAILY TAPE · CONCENTRATION FROM THE LATEST DISCLOSED BOOK
| Most-traded holdings, options premium | Bullish | Bearish |
|---|---|---|
| MRNA MODERNA | $52M | $54M |
| TEM TEMPUS AI INC | $11M | $17M |
| ILMN ILLUMINA | $4M | $6M |
| INSM INSMED | $5M | $2M |
| NTRA NATERA | $3M | $3M |
TODAY’S OPTIONS PREMIUM IN THE FUND’S UNDERLYING NAMES
Due diligence cuts both ways. These funds sit on the same shelf and beat BBH on at least one dimension that matters — the fee, the asset base, or where the money is going.
| Fund | Fee | Assets | Flow, 1M | The case | |
|---|---|---|---|---|---|
| SPDW State Street SPDR Portfolio Developed World ex-US ETF | 0.03% | $41B | +$286M | -32bp on fee · 85× the assets · +$286M in over the month | Head-to-head |
| SPMD State Street SPDR Portfolio S&P 400 Mid Cap ETF | 0.03% | $18.4B | +$199M | -32bp on fee · 38× the assets · +$199M in over the month | Head-to-head |
| IDEV iShares Core MSCI International Developed Markets ETF | 0.04% | $32.4B | +$497M | -31bp on fee · 67× the assets · +$497M in over the month | Head-to-head |
| IGSB iShares 1-5 Year Investment Grade Corporate Bond ETF | 0.04% | $23.3B | +$575M | -31bp on fee · 48× the assets · +$575M in over the month | Head-to-head |
| IGIB iShares 5-10 Year Investment Grade Corporate Bond ETF | 0.04% | $18.6B | +$412M | -31bp on fee · 39× the assets · +$412M in over the month | Head-to-head |